Related Resources for this page:
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- ResearchBcell
- Research B cell
- Prognostic indicators
- Current issues in CLL
- Diagnosing CLL
- Diffuse large B-cell lymphoma (DLBCL)
- The evolving CLL treatment landscape
- Follicular non-Hodgkin's lymphoma (fNHL)
- Goals of treatment
- Individualizing treatment
- Initiating treatment
- Emerging therapeutic options
- Chronic lymphocytic leukemia (CLL)
- Staging CLL
- ResearchBcell
- Clinical Trials
- Cancer Biomarkers
- Future Directions
- Antibody-Drug Conjugates
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Traditional Monoclonal Antibodies
- B-cell Surface Proteins
- Glossary
- Direct cell death
- Emerging therapeutic options
- Emerging therapeutic options
- The evolving CLL treatment landscape
- Gastric Cancer
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- Emerging therapeutic options
- Obinutuzumab (GA101)
Share
Chronic Lymphocytic Leukemia (CLL)
Disease Information
Genentech BioOncology is dedicated to advancing the science of CLL therapy through comprehensive research programs and education. CLL is the slow growth of malignant B-cell lymphocytes in the blood and bone marrow.1 There are 2 forms of CLL:
Forms of Chronic Lymphocytic Leukemia (CLL)
- CLL associated with high levels of ZAP-70 and CD38 proteins progresses relatively quickly. People with this form of CLL survive an average of about 8 years1
- CLL associated with lower levels of ZAP-70 and CD38 proteins progresses very slowly and rarely needs to be treated. People with this kind of CLL survive an average of 15 years or more1
Chronic Lymphocytic Leukemia (CLL) Demographics
- CLL is the most common form of adult leukemia, accounting for one-third of all leukemias in the United States2
- In 2010, an estimated 14,990 people in the United States were diagnosed with CLL and 4,390 died of the disease2
- The incidence of CLL has remained relatively stable since 19752
Chronic Lymphocytic Leukemia (CLL) Epidemiology
- Risk factors include exposure to certain chemicals (eg, Agent Orange, certain pesticides); family history (first-degree relatives of CLL patients have a 2- to 4-fold increased risk); male gender; North American or European ancestry (in contrast with Asian)1
- The 5-year relative survival rate for CLL is 79%2
The symptoms of CLL are often vague and nonspecific. They may include asthenia, fatigue, weight loss, fever, night sweats, enlarged lymph nodes, and enlarged spleen. Patients with advanced CLL may develop anemia, neutropenia, lymphocytosis, thrombocytopenia, and frequent infection.1
References:
- 1.
- American Cancer Society. Leukemia—chronic lymphocytic. www.cancer.org/Cancer/Leukemia-ChronicLymphocyticCLL/DetailedGuide/
leukemia-chronic-lymphocytic-what-is-cancer. Accessed April 12, 2011. - 2.
- American Cancer Society. Cancer Facts & Figures 2010. www.cancer.org/acs/groups/content/@epidemiologysurveilance/
documents/document/acspc-026238.pdf. Accessed April 14, 2011.